JP2026041921A5 - - Google Patents
Info
- Publication number
- JP2026041921A5 JP2026041921A5 JP2025238238A JP2025238238A JP2026041921A5 JP 2026041921 A5 JP2026041921 A5 JP 2026041921A5 JP 2025238238 A JP2025238238 A JP 2025238238A JP 2025238238 A JP2025238238 A JP 2025238238A JP 2026041921 A5 JP2026041921 A5 JP 2026041921A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- chemically synthesized
- smva
- genome
- full
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026127P | 2020-05-17 | 2020-05-17 | |
| US63/026,127 | 2020-05-17 | ||
| US202063044033P | 2020-06-25 | 2020-06-25 | |
| US63/044,033 | 2020-06-25 | ||
| US202063113810P | 2020-11-13 | 2020-11-13 | |
| US63/113,810 | 2020-11-13 | ||
| US202163161371P | 2021-03-15 | 2021-03-15 | |
| US63/161,371 | 2021-03-15 | ||
| JP2022570108A JP7788403B2 (ja) | 2020-05-17 | 2021-05-17 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| PCT/US2021/032821 WO2021236550A1 (en) | 2020-05-17 | 2021-05-17 | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570108A Division JP7788403B2 (ja) | 2020-05-17 | 2021-05-17 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026041921A JP2026041921A (ja) | 2026-03-10 |
| JP2026041921A5 true JP2026041921A5 (https=) | 2026-03-17 |
Family
ID=78708032
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570108A Active JP7788403B2 (ja) | 2020-05-17 | 2021-05-17 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
| JP2025238238A Pending JP2026041921A (ja) | 2020-05-17 | 2025-12-08 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570108A Active JP7788403B2 (ja) | 2020-05-17 | 2021-05-17 | 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230323389A1 (https=) |
| EP (1) | EP4153228A4 (https=) |
| JP (2) | JP7788403B2 (https=) |
| KR (1) | KR20230012583A (https=) |
| CN (1) | CN116348132A (https=) |
| AU (1) | AU2021276265A1 (https=) |
| BR (1) | BR112022023173A2 (https=) |
| CA (1) | CA3183016A1 (https=) |
| IL (1) | IL298210A (https=) |
| MX (1) | MX2022014387A (https=) |
| WO (1) | WO2021236550A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| WO2023056284A1 (en) * | 2021-09-29 | 2023-04-06 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronavirus infection |
| WO2023092021A1 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
| EP4558171A1 (en) * | 2022-07-22 | 2025-05-28 | City of Hope | Synthetic modified vaccinia ankara vaccines to stimulate orthopox and monkeypox virus immunity |
| EP4316514A1 (en) * | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
| TW202426045A (zh) * | 2022-10-07 | 2024-07-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物 |
| WO2026030724A1 (en) * | 2024-08-01 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014034A1 (en) | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| EP2363493B1 (en) | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US20070092936A1 (en) * | 2003-05-08 | 2007-04-26 | Haynes Barton F | Severe acute respiratory syndrome |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2006071250A2 (en) * | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble fragments of the sars-cov spike glycoprotein |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| EP3045181B1 (en) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| WO2017209053A1 (ja) | 2016-05-30 | 2017-12-07 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| WO2019014569A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS |
| EP3788142A4 (en) * | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| CA3168836A1 (en) | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| IL295548A (en) * | 2020-02-14 | 2022-10-01 | Altimmune Inc | Immunogenic compositions of the corona virus and their uses |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| KR20220165731A (ko) * | 2020-02-26 | 2022-12-15 | 토닉스 파마 리미티드 | Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신 |
| WO2021178416A1 (en) * | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
| US11202753B1 (en) * | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
| JP2023517286A (ja) | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 免疫応答を誘導するための組成物及び方法 |
| US20210299245A1 (en) | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| US20230143228A1 (en) | 2020-04-21 | 2023-05-11 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
-
2021
- 2021-05-17 EP EP21809653.5A patent/EP4153228A4/en active Pending
- 2021-05-17 US US17/999,170 patent/US20230323389A1/en active Pending
- 2021-05-17 BR BR112022023173A patent/BR112022023173A2/pt unknown
- 2021-05-17 KR KR1020227044240A patent/KR20230012583A/ko active Pending
- 2021-05-17 WO PCT/US2021/032821 patent/WO2021236550A1/en not_active Ceased
- 2021-05-17 JP JP2022570108A patent/JP7788403B2/ja active Active
- 2021-05-17 MX MX2022014387A patent/MX2022014387A/es unknown
- 2021-05-17 CA CA3183016A patent/CA3183016A1/en active Pending
- 2021-05-17 AU AU2021276265A patent/AU2021276265A1/en active Pending
- 2021-05-17 IL IL298210A patent/IL298210A/en unknown
- 2021-05-17 CN CN202180059838.6A patent/CN116348132A/zh active Pending
-
2025
- 2025-04-18 US US19/183,257 patent/US12584146B2/en active Active
- 2025-12-08 JP JP2025238238A patent/JP2026041921A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041921A5 (https=) | ||
| JP2023526073A5 (https=) | ||
| CA2074502C (en) | Vaccines | |
| JP3681753B2 (ja) | 異種ペプチドのベクターとしての改質植物ウイルス | |
| US5616326A (en) | Recombinant canine adenovirus 2 (CAV-2) | |
| JP2023512519A5 (https=) | ||
| KR101196178B1 (ko) | Ｈｉｖ 조절/부속 단백질의 융합 단백질 | |
| JP2023512294A5 (https=) | ||
| EP3524682A1 (en) | Recombinant marek's disease viruses and uses thereof | |
| JP2009213495A (ja) | 組換えブタ・アデノウイルス・ベクター | |
| JP2013507935A5 (https=) | ||
| ES2623149T3 (es) | Parvovirus atenuado vivo | |
| JP2025508676A5 (https=) | ||
| CN114395569A (zh) | 一种腺病毒载体重组新冠病毒b.1.1.529变异株疫苗及其应用 | |
| WO2022079160A2 (en) | Recombinant hvt and uses thereof | |
| JP2024535145A (ja) | 改変ワクシニアウイルスアンカラ（ｍｖａ）による細胞傷害性導入遺伝子発現を下方調節するためのマイクロｒｎａの利用 | |
| JPH03164182A (ja) | 新規な抗原性的活性タンパク質／ペプチド、およびネコの感染性腹膜炎ウイルス（ｆｉｐｖ）―ワクチン | |
| CN106011087B (zh) | S1基因和tm-1基因重组腺病毒的构建方法及重组腺病毒和应用 | |
| Allmansberger et al. | Arrangement and expression of methyl CoM reductase genes in Methanococcus voltae | |
| CN117625689B (zh) | 表达ibdv vp2蛋白的b亚型禽偏肺病毒疫苗株 | |
| US20080267992A1 (en) | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine | |
| WO2024114673A1 (zh) | 一种水泡性口炎病毒的致弱方法及致弱病毒株和应用 | |
| CN111875678A (zh) | 表达猪繁殖与呼吸综合征病毒gp3/gp5/m基因的重组伪狂犬病毒、构建方法和应用 | |
| Cavanagh et al. | Molecular basis of the variation exhibited by avian infectious bronchitis coronavirus (IBV) | |
| CN1208340C (zh) | 3型人副流感病毒的感染性克隆 |